Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Other Operating Expenses (2017 - 2025)

Puma Biotechnology's Other Operating Expenses history spans 9 years, with the latest figure at $23.1 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 66.13% year-over-year to $23.1 million; the TTM value through Dec 2025 reached $58.2 million, down 9.7%, while the annual FY2025 figure was $58.2 million, 9.7% down from the prior year.
  • Other Operating Expenses reached $23.1 million in Q4 2025 per PBYI's latest filing, up from $12.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $29.6 million in Q1 2021 to a low of $10.3 million in Q3 2021.
  • Average Other Operating Expenses over 5 years is $15.8 million, with a median of $12.8 million recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: soared 225.66% in 2021, then tumbled 63.31% in 2022.
  • A 5-year view of Other Operating Expenses shows it stood at $11.9 million in 2021, then surged by 41.54% to $16.8 million in 2022, then skyrocketed by 44.47% to $24.3 million in 2023, then tumbled by 42.77% to $13.9 million in 2024, then surged by 66.13% to $23.1 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Other Operating Expenses are $23.1 million (Q4 2025), $12.2 million (Q3 2025), and $12.3 million (Q2 2025).